Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have revolutionized cancer care. However, assessing the efficacy of these new molecules with targeted therapeutic responses may induce too much delay when using classical biomarkers derived from morphological imaging (CT). The objective of our study...

Descripción completa

Detalles Bibliográficos
Autores principales: Naccache, Raphael, Belkouchi, Younes, Lawrance, Littisha, Benatsou, Baya, Hadchiti, Joya, Cournede, Paul-Henry, Ammari, Samy, Talbot, Hugues, Lassau, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909556/
https://www.ncbi.nlm.nih.gov/pubmed/35267645
http://dx.doi.org/10.3390/cancers14051337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909556/
https://www.ncbi.nlm.nih.gov/pubmed/35267645
http://dx.doi.org/10.3390/cancers14051337

Ejemplares similares